Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s. by Djaloul Karboua (16510091)

“…<p>Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.…”

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Quantification of <i>ATP5B</i> mRNA and β-F1-ATPase protein expression shows decreased protein translation in obesity. by Lee Tran (2106961)

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

Propofol induced cell death and decreased mitochondrial membrane potential in a concentration- and time-dependent manner. by Chisato Sumi (3521705)

LuxR G37V has decreased DNA-binding activity. by Chelsea A. Simpson (9579303)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Protein 169 increases 80S monosomes and decreases polysomes. by Pavla Strnadova (383776)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Concentrations of particles that caused significant decreases in the viability of SNU-1 cells compared to untreated cells during 1, 2, 4, 6 or 24 h treatment periods. by Amrita Banerjee (382658)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

DMB treatment decreased neuronal apoptosis in cerebral ischemia. by Huinan Zhang (849524)

Corticosterone treatment decreases MMP-2 promoter activity. by Eric A. Shikatani (131260)

“…MMP-2 mRNA levels were decreased with corticosterone treatment (A) (p = 0.006, n = 5). …”

ROS and superoxide decrease in the dormant form of mycobacteria. by Amar Yeware (7115063)

Tranilast decreases RANKL-induced ROS level. by Tien Van Phan (583324)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)